Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial

Thymic carcinoma is a cancer of the thymus epithelium with a poor prognosis, and is both biologically and pathologically distinct from thymoma [1,2]. The disease has an incidence of approximately 0.03 per 100,000 people per year, meeting the definition of a rare cancer [3 –5]. The Japanese Society of Thoracic Surgery reported that thymic carcinoma accounted for 0.3 % of lung cancer surgeries in 2008 [6].

Source: Lung Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto Source Type: research